Stock Yearly Return 2018
Start date: 01/02/2018
End date: 12/31/2018
Start price/share: $9.98
End price/share: $5.57
Dividends collected/share: $0.00
Total return: -44.19%
SYRS Average Annual Return: -44.43%
Starting investment: $10,000.00
Ending investment: $5,581.00
Years: 0.99


SYRS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare SYRS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into SYRS


Also see:
SYRS stock yearly return 2019
SYRS stock yearly return 2020
SYRS YTD return
SYRS average annual return 10 years
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a pipeline of gene control medicines. Co.'s primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine, a hypomethylating agent frequently used to treat acute myeloid leukemia; and SY-5609, a selective oral inhibitor of cyclin-dependent kinase 7, that is being evaluated in the dose escalation portion of a clinical trial in patients with select advanced solid tumors. The SYRS stock yearly return is shown above.

The yearly return on the SYRS stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2018 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the SYRS annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for SYRS:
SYRS SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Syros Pharmaceuticals (SYRS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

TARO Average Annual Return
TBIO Average Annual Return
TCMD Average Annual Return
TCON Average Annual Return
TDOC Average Annual Return
TECH Average Annual Return
TENX Average Annual Return
TEVA Average Annual Return
TFX Average Annual Return
TGTX Average Annual Return
More Healthcare companies »

 

SYRS Stock Yearly Return 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.